{"name":"Grupo de Estudos Multicentricos em Onco-Hematologia","slug":"grupo-de-estudos-multicentricos-em-onco-hematologia","ticker":"","exchange":"","domain":"","description":"Grupo de Estudos Multicentricos em Onco-Hematologia is a research-focused organization dedicated to advancing treatments in oncology and hematology through multicenter clinical trials. The group has contributed significantly to the development of several key drug combinations, particularly in phase 3 trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Thalidomide plus dexamethasone","genericName":"Thalidomide plus dexamethasone","slug":"thalidomide-plus-dexamethasone","indication":"Multiple myeloma (newly diagnosed or relapsed/refractory)","status":"phase_3"},{"name":"Bortezomib, cyclophosphamide, thalidomide, dexamethasone","genericName":"Bortezomib, cyclophosphamide, thalidomide, dexamethasone","slug":"bortezomib-cyclophosphamide-thalidomide-dexamethasone","indication":"Multiple myeloma (newly diagnosed or relapsed/refractory)","status":"phase_3"},{"name":"Thalidomide, Cyclophosphamide, Dexamethasone","genericName":"Thalidomide, Cyclophosphamide, Dexamethasone","slug":"thalidomide-cyclophosphamide-dexamethasone","indication":"Multiple myeloma","status":"phase_3"},{"name":"Thalidomide, Dexamethasone","genericName":"Thalidomide, Dexamethasone","slug":"thalidomide-dexamethasone","indication":"Multiple myeloma","status":"phase_3"},{"name":"Thalidomide, Melphalan, Prednisone","genericName":"Thalidomide, Melphalan, Prednisone","slug":"thalidomide-melphalan-prednisone","indication":"Multiple myeloma in patients ineligible for autologous stem cell transplantation","status":"phase_3"}]}],"pipeline":[{"name":"Thalidomide plus dexamethasone","genericName":"Thalidomide plus dexamethasone","slug":"thalidomide-plus-dexamethasone","phase":"phase_3","mechanism":"Thalidomide acts as an immunomodulatory agent and cereblon E3 ligase ligand, while dexamethasone provides corticosteroid-mediated anti-inflammatory and immunosuppressive effects.","indications":["Multiple myeloma (newly diagnosed or relapsed/refractory)","Light chain myeloma"],"catalyst":""},{"name":"Bortezomib, cyclophosphamide, thalidomide, dexamethasone","genericName":"Bortezomib, cyclophosphamide, thalidomide, dexamethasone","slug":"bortezomib-cyclophosphamide-thalidomide-dexamethasone","phase":"phase_3","mechanism":"This combination regimen targets multiple pathways in multiple myeloma by inhibiting proteasome function, inducing DNA damage, suppressing tumor necrosis factor, and providing immunomodulatory effects.","indications":["Multiple myeloma (newly diagnosed or relapsed/refractory)"],"catalyst":""},{"name":"Thalidomide, Cyclophosphamide, Dexamethasone","genericName":"Thalidomide, Cyclophosphamide, Dexamethasone","slug":"thalidomide-cyclophosphamide-dexamethasone","phase":"phase_3","mechanism":"Thalidomide is a glutamic acid derivative that inhibits tumor necrosis factor-alpha (TNF-alpha) production, while Cyclophosphamide is an alkylating agent that interferes with DNA replication, and Dexamethasone is a corticosteroid that suppresses inflammation and immune response.","indications":["Multiple myeloma","Mantle cell lymphoma"],"catalyst":""},{"name":"Thalidomide, Dexamethasone","genericName":"Thalidomide, Dexamethasone","slug":"thalidomide-dexamethasone","phase":"phase_3","mechanism":"Thalidomide inhibits the release of tumor necrosis factor-alpha (TNF-alpha), a cytokine involved in inflammation and immune response.","indications":["Multiple myeloma","Erythema nodosum leprosum"],"catalyst":""},{"name":"Thalidomide, Melphalan, Prednisone","genericName":"Thalidomide, Melphalan, Prednisone","slug":"thalidomide-melphalan-prednisone","phase":"phase_3","mechanism":"This combination uses thalidomide as an immunomodulatory agent, melphalan as an alkylating chemotherapy, and prednisone as a corticosteroid to treat multiple myeloma through multiple mechanisms including immune activation, DNA damage, and anti-inflammatory effects.","indications":["Multiple myeloma in patients ineligible for autologous stem cell transplantation"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":5},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}